We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lombard Med.Tec | LMT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 188.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 188.50 | 188.50 |
| Top Posts |
|---|
Posted at 04/4/2014 07:08 by 25october1969 My guess, knowing the way the markets work, is that the price rise over the last two days is due to "insiders" knowing that they have got the placing away at a good price. Next task is to make sure that price does not fall on listing so I hope they sold a good story to US investors |
Posted at 21/1/2014 03:01 by nod Getting closer to the USLombard Medical Technologies', (LMMT) decision to list in the US is a clear response to the positive initial reaction to the launch of the Aorfix high angle stent. The commercial importance of the US market coupled with the existence of a defined peer group, including direct comparator Endologix, could provide a receptive market for the IPO. The US roll-out is progressing well and the case pipeline is building, while sales in the main European markets increased 9% in FY13. We have maintained our valuation at £119m.Lombard Medical ChartUS roll-out off to a solid startAorfix, the only FDA-approved stent graft for aortic neck angles over 60°, was launched formally in the US in November 2013 at the Veith Symposium for vascular surgeons. Lombard has a direct sales team in place, marketing Aorfix to c 300 high volume endovascular centres in the region. In the initial period, Lombard trained a total 244 surgeons. The roll-out is still in its early stages, but US sales already contributed to 38% Q413 sales growth and the patient pipeline is building well.European and rest of world trading environmentSales of Aorfix grew 25% to £3.9m, including 9% growth in the main European markets. UK sales recovered from last year on completion of the NHS restructuring of specialised centres. The strongest markets were Germany, where Lombard has a direct sales force, and Spain. Rest of world trading increased 28%. Total revenue was £4.5m, compared to our forecast of £5m, mainly due to slower than expected trading in the OEM business (which was divested in December).Nasdaq IPOLombard's intention to list in the US and to delist from UK AIM market should provide greater exposure to investors in Aorfix's key market (estimated at $700m), as well as additional liquidity for the shares. The company will invest the IPO proceeds to accelerate its commercialisation of Aorfix in the US. It will also invest in the product pipeline, including the development of a thoracic stent graft. The launch into Japan, the world's second-largest aortic stent market, is on track for 2014.Valuation: Held at £119mOur valuation is held at £119m (267p/share). We have adjusted our FY13 sales and expenses based on the trading update. A US listing could provide a boost for the shares in line with US peers; Endologix has a valuation of over $1.1bn (FY12 sales of $101m). |
Posted at 08/1/2014 08:27 by nod Is the decision to de-list from London and move to Nasdaq designed to make a sale to a US company more straightforward?The reason is not an obvious one. They are currently expanding manufacturing in Didcot suggesting a long term commitment to UK manufacturing, yet de-listing from London.Are they simply disillusioned with the lack of interest from UK investors.I'm happy to move to Nasdaq - I suspect there will be more interest in LMT from US investors. It will also be good if the USD rises against the GBP. |
Posted at 18/11/2013 07:17 by skinny The Only FDA Approved Endovascular Stent Graft for Use in Challenging Abdominal Aortic Aneurysm CasesLondon, UK and Irvine, CA, November 18, 2013 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on the treatment of abdominal aortic aneurysms (AAAs), today announces a stand-alone symposium and program of presentations to mark the formal US launch of Aorfix, the Company's flexible stent graft, at the 40th Annual VEITH Symposium, November 19-23, New York Hilton Midtown Hotel, Manhattan, New York City. CEO of Lombard Medical Technologies, Simon Hubbert, commented: "Published clinical data suggest that up to 30% of patients present with tortuous AAA anatomy. US physicians now have access to Aorfix, a highly effective, FDA approved treatment option for such cases. VEITH Symposium is one of the most important annual gatherings of vascular surgeons from around the world and the ideal venue to formally launch Aorfix in the US." Aorfix was approved by the US FDA in February this year and includes a unique label indication for the treatment of patients with neck angulations up to and including 90 degrees. Lombard Medical will be hosting a launch stand-alone symposium, where leading physicians will present clinical data and provide their first-hand experience of Aorfix, on Thursday November 21, 12:00 noon to 1:00 PM. Clinical discussions at the launch stand-alone symposium will be led by key investigators from the Pythagoras US clinical trial of Aorfix, including: · Overall 1-year results of the Aorfix Pythagoras PMA Study - Mark F. Fillinger, M.D. Director, Vascular Surgery Training Programs, Professor of Surgery, Geisel School of Medicine, Dartmouth and Principal Investigator for Lombard's PMA Trial · Anatomical angles and effect on Aorfix PMA Study results - Mahmoud B. Malas, M.D. Chief of Endovascular Surgery and Director of Vascular and Endovascular Clinical Research, Johns Hopkins Bayview Medical Center · Gender and its impact on Aorfix PMA Study outcomes - William D. Jordan Jr., M.D. Professor of Vascular Surgery, University of Alabama School of Medicine · Access techniques for tortuous anatomy - Jeffrey P. Carpenter, M.D. Chairman and Chief, Department of Surgery, Cooper University Health Care · Clinical insights from the Aorfix PMA Study - Kim J. Hodgson, M.D. Professor and Chair, Division of Vascular Surgery, SIU School of Medicine In addition, Lombard Medical will host a meeting and product demonstration for investors and analysts on November 20, 2:30 PM to 4:30 PM at the Hilton hotel, no new material financial or other information will be disclosed. The following presentations highlighting Aorfix will also take place at this year's VEITH Symposium on Friday November 22: · Advantages and Limitations of the Lombard Aorfix Endograft. Now FDA Approved in the US - Mark F. Fillinger, M.D. Director, Vascular Surgery Training Programs, Professor of Surgery, Geisel School of Medicine, Dartmouth and Principal Investigator for Lombard's PMA Trial · Challenging Anatomy: Can Freedom from Adjunctive Fixation mean Freedom from Migration and Endoleak? - Prof. Brian R. Hopkinson, M.D., Emeritus Professor of Vascular Surgery, University of Nottingham; Consultant Vascular Surgeon, Queen's Medical Centre, Nottingham, United Kingdom -Ends- |
Posted at 17/8/2013 02:26 by nod Old news from last month that popped up on my alerts today. Old but worth a reminder of the targets set by Cannaccord 243p and Panmure 321p only a month ago.Lombard Medical Technologies PLC (LON: LMT)'s stock had its "buy" rating reaffirmed by equities researchers at Canaccord Genuity in a research report issued on Monday, ARN reports. They currently have a GBX 243 ($3.67) price objective on the stock. Canaccord Genuity's target price points to a potential upside of 38.86% from the company's current price.Separately, analysts at Panmure Gordon reiterated a "buy" rating on shares of Lombard Medical Technologies PLC in a research note to investors on Tuesday, May 7th. They now have a GBX 321 ($4.85) price target on the stock.http://www.wat |
Posted at 07/6/2013 09:14 by stable Investors Chronicle yesterday, LMT a buy, does a lot of good I notice this morning. |
Posted at 08/5/2013 04:11 by nod Lombard Medical Technologies PLC (LON: LMT)'s stock had its "buy" rating reiterated by equities research analysts at Panmure Gordon in a research note issued to investors on Tuesday, Stock Ratings Network reports. They currently have a GBX 321 ($5.00) price target on the stock.Separately, analysts at Canaccord Genuity reiterated a "buy" rating on shares of Lombard Medical Technologies PLC in a research note to investors on Friday, March 22nd. They now have a GBX 326.88 ($5.09) price target on the stock.Lombard Medical Technologies PLC (LON: LMT) opened at 203.95 on Tuesday. Lombard Medical Technologies PLC has a 52-week low of GBX 52.00 and a 52-week high of GBX 250.00. The stock's 50-day moving average is currently GBX 108.8.http://zolmax. |
Posted at 26/3/2013 13:27 by rayrac Does this look interesting, or does it?About Us Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies. Founded in 1973, Abingworth has a lengthy track record of building market leading companies. Our specialist team of over 20 professionals has a broad range of skills, including scientific and business expertise as well as investment banking, recruitment and legal knowledge. These resources are made available to portfolio companies. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park (California) and Boston. Venture Capital Growth Equity Public Markets Edwin Moses, Portfolio Company Chairman and former CEO of Oxford Asymmetry I am currently working with Abingworth in four of the companies in which they have invested. They are absolutely consistent in their enthusiastic and knowledgeable support and commitment. Most impressively, they have differentiated themselves dramatically from other investors by being able to provide their companies with in-house access to a wide variety of critical specialist expertise in the areas of entrepreneurial management, technical, legal, human resources, M&A and finance. Abingworth is far more than a provider of cash just looking for a return. It is a partner with integrity focused on growing genuine value in developing biotechnology companies. |
Posted at 19/3/2013 20:08 by nod Remember also that we all had the opportunity over the past two years to buy shares at much the same price as these qualifying investors and the employees who stumped up several million quid at 140p - 0.7p old money. My average is not much more than these guys who took much bigger risks than I did. They deserve their profits although in the interest of equality and fairness I would have liked to have seen open offers to shareholders. |
Posted at 19/10/2012 21:33 by nod Date: Thursday 18 Oct 2012LONDON (ShareCast) - This week has seen a 40% rise in the share price of Lombard Medical Technology, following an update on October 15th that had well respected healthcare analyst Julie Simmonds pushing out a Buy note, maintaining her price target of 332p. Admittedly, she works for the house broker Canaccord Genuity, but anyone who has followed her recommendations over the course of a few years will take note of her views on a company. In a 14-year career she's been Head of Lifesciences Research at Evolution Beeson Gregory, an Equity Analyst at Nomura, Senior Research Analyst at Piper Jaffray and is now Healthcare Analyst at Canaccord Genuity. With a a Phd in Microbiology she can also assess the science as well as crunch numbers. Announcement For those who missed the announcement: the Aim-listed company has received written feedback from the FDA asking a couple of questions, which the company says are "relatively straightforward". Lombard Medical intends to answer them within two weeks. In addition, the FDA has scheduled a Good Manufacturing Process audit of the company's UK facility in late October. The company states that such audits are "typically part of the final stage of the FDA's review process." Analyst assessment So what does Simmonds have to say about the latest development for Lombard? She believes it "marks the closing stages of the FDA process." She continues: "We are encouraged that a date has been set for the manufacturing audit as we believe this signals that the remainder of the submission is in order. With this due to be completed in late October, 2012 approval is certainly still possible, though likely late Q4/ early Q1-13. The timing of the final FDA decision is particularly critical to Lombard as it triggers a second tranche of funding (£13.6m) from existing investors if it occurs prior to the year end. After this date the funding falls away, but discussions with investors lead us to believe that they would remain supportive." Make no mistake, it has been a tortuous process that has taken years. Without the support of long term investors, such as Invesco Perpetual, which holds 39.28% of Lombard, this story would not be likely to have a happy ending. "Our investment case is based on Lombard receiving FDA approval for Aorfix at the end of the fourth quarter. We expect a positive FDA outcome to result in a rerating; the current price only assumes a 20-40% chance of a positive result," she adds. Clearly, it still isn't in the bag until the FDA sings but it is close. Very close. Writing on October 15th when the price was 101p, she commented: "Our investment case is based on Lombard receiving FDA approval for Aorfix at the end of the fourth quarter. We expect a positive FDA outcome to result in a rerating; the current price only assumes a 20-40% chance of a positive result." That re-rating higher appears to be happening. Nevertheless, the recent spike in Lombard's share price has occurred on very low volumes given the tightly held nature of the company's stock. Moreover, US approval when it comes (and it must surely be 'when', not 'if', in my humble opinion) would open up a huge market for Lombard Medical's aorfix stent. This is Julie Simmonds view: "The opportunity for Lombard is substantial. Aorfix is designed to treat patients with high angle abdominal aortic aneurysms, no other device is approved in the US for this indication. An approval with labelling for this patient group would make Aorfix the only FDA approved product for these complex patients, circa 30% of the $1.1bn AAA repair market, 54% of which is in the US. We believe this would result in a rapid adoption the US (the device already has an 8%+ market share in the UK), and ultimately bring Lombard to the attention of the medical device majors." Ultimately this is the end game, to be taken out by one of the majors. US approval when it comes should bring this one step closer. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
